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Abstract
Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of
the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available
antifungals is limited, and antifungal-resistant Candida strains are emerging. New and effective antifungals are therefore
urgently needed. Here, we discovered a small molecule with activity against Candida spp. both in vitro and in vivo. We
screened a library of 50,240 small molecules for inhibitors of yeast-to-hypha transition, a major virulence attribute of
Candida albicans. This screening identified 20 active compounds. Further examination of the in vitro antifungal and anti-
biofilm properties of these compounds, using a range of Candida spp., led to the discovery of SM21, a highly potent
antifungal molecule (minimum inhibitory concentration (MIC) 0.2 – 1.6 mg/ml). In vitro, SM21 was toxic to fungi but not to
various human cell lines or bacterial species and was active against Candida isolates that are resistant to existing antifungal
agents. Moreover, SM21 was relatively more effective against biofilms of Candida spp. than the current antifungal agents. In
vivo, SM21 prevented the death of mice in a systemic candidiasis model and was also more effective than the common
antifungal nystatin at reducing the extent of tongue lesions in a mouse model of oral candidiasis. Propidium iodide uptake
assay showed that SM21 affected the integrity of the cell membrane. Taken together, our results indicate that SM21 has the
potential to be developed as a novel antifungal agent for clinical use.
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Introduction
Candida is the most common fungal pathogen of humans and the
fourth leading pathogen in nosocomial bloodstream infections [1].
It causes a wide range of infections, from invasive to superficial, at
various anatomical sites [2]. Invasive candidiasis is associated with
high mortality among immunocompromised populations, and
superficial mucosal candidiases are highly prevalent and persistent,
especially among immunocompromised patients. The most
common superficial candidiases are oral candidiasis and Candida-
associated denture stomatitis [3–5]. Candida-associated denture
stomatitis could affect up to 70% of denture wearers [6].
The most prevalent candidiasis-causing species is Candida
albicans. It has a versatile morphogenesis, existing in three forms
(i.e., yeasts, pseudohyphae and hyphae), and has two lifestyles
(planktonic and biofilm), permitting C. albicans to thrive under
diverse environmental conditions. In particular, the yeast-to-hypha
(Y-H) transition is a major virulence attribute that facilitates tissue
invasion by C. albicans [7,8]. In addition to Y-H transition, biofilm
formation on host tissue or abiotic devices is also a significant basis
for Candida infections [5], examples include Candida-associated
denture stomatitis [9]. The formation of Candida biofilms, which
are more resistant to antifungal agents than planktonic cells, is
directly associated with treatment failure [5,10]. Although Candida
infections have always posed a heavy burden on public health, this
situation has recently worsened. First, the worldwide incidence of
candidiasis has been increasing over the past few decades [11],
which may be attributable to increased numbers of immunocom-
promised patients and the use of broad-spectrum antibiotics [12].
Second, the increased incidence of invasive candidiasis caused by
non-albicans Candida (NAC) species, such as Candida glabrata, Candida
tropicalis, Candida krusei or Candida parapsilosis, has been a major
concern [13,14], because these infections are often associated with
higher mortality and antifungal resistance than those caused by C.
albicans [15,16]. Lastly, the emergence of antifungal resistance and
treatment side effects have further restricted treatment options
because of the already limited arsenal of current antifungal agents
[17,18].
Only a few classes of antifungal drugs (polyenes, azoles,
echinocandins, allylamines and DNA analogues) are available for
candidiasis treatment [19], but these drugs are far from ideal.
Polyenes, for example, have dose-related toxicity, particularly
nephrotoxicity (even though the recent introduction of lipid
formulations has now improved the risk-benefit ratio) [20]. In
addition, rising drug resistance is an inevitable problem. This is
pertinent for fluconazole, a drug of choice for treating AIDS
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patients with Candida infections. While C. glabrata and C. krusei are
intrinsically resistant to fluconazole, the emergence of fluconazole-
resistant C. albicans strains is also on the rise [21,22]. Similarly,
emerging resistance has also been reported for the more recently
introduced echinocandins [23–26]. Therefore, the situation is
likely to be ameliorated only by the discovery and introduction of
safe and new antifungal agents.
Small molecules are an invaluable source of novel antifungal
agents [27]. Previous screening of the same small-molecule library
has resulted in the identification of novel compounds effective for
severe acute respiratory syndrome-associated coronavirus [28].
Here, we sought small molecules with anti-Candida properties (with
the overall strategy depicted in Figure 1). We first screened a
collection of over 50,000 small molecules for inhibitors of the Y-H
transition in C. albicans. The identified hits were further assessed
for antifungal and anti-biofilm activity, which led us to discover a
novel antifungal small molecule, which we designated SM21. We
examined the in vitro antifungal activity of SM21, as well as its in
vivo efficacy in mouse infection models of oral and systemic
candidiases. Last, the potential mechanism of action of SM21 was
also investigated.
Materials and Methods
High-throughput screening for Candida Y-H inhibitors
High-throughput screening was performed at the Chemical
Genetics Unit, Department of Microbiology, Research Center of
Infection and Immunology, Li Ka Shing Faculty of Medicine,
University of Hong Kong, on a library with 50,240 small
molecules (ChemBridge, San Diego, CA, USA) to identify
inhibitors of Y-H transition in C. albicans SC5314, as was
previously described [29]. C. albicans SC5314 were seeded at
56103 cells per well in complete yeast peptone dextrose (YPD)
(1% yeast extract, 2% peptone, 2% glucose/dextrose) supple-
mented with 20% heat-inactivated foetal bovine serum (Invitro-
gen, Carlsbad, CA, USA) in a total volume of 50 ml in 384-well
microtitre plates. The small molecules were dissolved in dimethyl
sulfoxide (DMSO) and were added to the wells at final
concentration of 20 mg/ml, whereas the controls contained the
same amount of DMSO but without small molecules. Assay plates
were incubated at 37uC in 5% CO2 for 12 h. Morphologies of the
Candida were scored using a Leica DMIL inverted microscope
equipped with DC300F digital imaging system (Leica Micro-
systems, Heidelberg, Germany). Small molecules with lower scores
than that of the control (yeast-to-hypha transition inhibitors) were
selected as primary hits.
Further evaluation of Y-H inhibition of the primary hits
Dose-dependent Y-H inhibition by the primary hits was further
examined using the reference strain C. albicans SC5314 and ten
clinical isolates of C. albicans (strains CL1 – CL10, of oral origin
from the archival collection of Oral Biosciences, Faculty of
Dentistry, University of Hong Kong) under robust hypha-inducing
conditions (Lee’s medium [30] and 37uC incubation). Each sample
contained 100 ml of Candida suspension (16106 CFUs/ml) and
100 ml of the small molecules of different final concentrations (3.13
– 25 mg/ml). After incubation for 24 h, cell morphologies were
observed by light microscopy (Olympus BH-2, Tokyo, Japan). The
degree of Y-H inhibition was quantified by calculating the
percentage of hyphal cells in one hundred cells in a single sample
[29]. Counting was performed in quadruplicate for each sample.
The minimum inhibitory concentration (MIC) of Y-H transition
(MICY-H) was determined as the minimum concentration at which
no hyphae were observed. The assay was performed on three
different occasions in duplicate.
Antifungal susceptibility tests of the small molecules
The antifungal activity of small molecules was assessed by disk
diffusion and broth dilution assays (see below) using four groups of
Candida isolates. The first group consisted of ATCC strains: C.
albicans ATCC 90028 (quality control strain), C. glabrata ATCC
90030, C. krusei ATCC 6258, C. parapsilosis ATCC 22019 and C.
tropicalis ATCC 13803.
The other three groups were clinical isolates: 92 bloodstream
isolates (Queen Mary Hospital and Queen Elizabeth Hospital,
Hong Kong), 46 oral isolates from nasopharyngeal carcinoma
patients (Queen Mary Hospital, Hong Kong) and 10 denture
stomatitis clinical isolates (from the archival collection of Oral
Biosciences, Faculty of Dentistry, University of Hong Kong). All of
the isolates were subcultured on Sabouraud dextrose agar (SDA)
and were incubated aerobically at 37uC overnight before the
Figure 1. Strategy for screening for novel antifungal small
molecules. We screened for Y-H inhibitors in a library containing
50,240 small molecules and found 20 active compounds. These 20
primary hits were further validated by assessing their activity in a dose-
dependent manner, which led to the identification of eight potent Y-H
inhibitors. The antifungal properties of the eight compounds were
analysed in antifungal susceptibility tests, and the four most potent
molecules were selected. Finally, the anti-biofilm activity of the four hits
was evaluated, and SM21 was chosen for comprehensive in vitro and in
vivo assays. HTS, high-throughput screening; AST, antifungal suscepti-
bility test; ABT, anti-biofilm test.
doi:10.1371/journal.pone.0085836.g001
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assay. All of the assays were performed on three different occasions
in duplicate per isolate.
Disk diffusion assay
The standard disk diffusion assay (Clinical and Laboratory
Standards Institute (CLSI) M44-A2) was used. In brief, a
16106 CFUs/ml yeast suspension was prepared for each isolate
in phosphate-buffered saline (PBS) and distributed evenly by a
spiral plater on Mueller-Hinton (M-H) agar supplemented with
2% glucose and 0.5 mg/ml methylene blue. Antifungal tablets
(10 mg amphotericin B, 5 mg caspofungin, 15 mg ketoconazole and
25 mg fluconazole) (Neo-Sensitabs, Rosco Diagnostica, Taastrup,
Denmark) were used as positive controls. Paper coupons were
placed on the agar, and either 2 mg of the small molecule or PBS
(as a negative control) was added onto the coupons. The M-H agar
plates were then incubated aerobically at 37uC for 24 h, and
diameters of the resultant inhibition zones were measured.
Broth dilution assay
The standard protocol for broth microdilution assay (CLSI
M27-A3) was followed with modifications [31]. Yeast suspensions
(approximately 16103 colony forming units per millilitre (CFUs/
ml)) were prepared in RPMI 1640 medium (Life Technologies,
New York, USA) and were added to a 96-well microtitre plate
(Iwaki, Tokyo, Japan). Serial dilutions of the small molecules were
prepared with the medium and added to the wells. Amphotericin
B was used as a positive control. The plate was incubated at 37uC
for 48 h, and then Candida growth on the well bottoms was visually
observed to determine the minimum inhibitory concentration
(MIC). Activity against Cryptococcus neoformans, Aspergillus fumigatus
and Penicillium marneffei was similarly assessed after 72 h of
incubation.
Anti-biofilm assay in microtitre plates
Candida biofilms were formed according to a previously
described method [32]. In brief, yeast cells were subcultured on
SDA and incubated at 37uC aerobically for 18 h. They were then
transferred to yeast nitrogen base (YNB) liquid medium supple-
mented with 50 mM glucose, and incubated aerobically at 37uC,
75 rpm overnight. The harvested cells were washed twice with
10 ml PBS and were resuspended to a density of 16107 CFUs/ml
in YNB medium supplemented with 100 mM glucose. Each of the
wells of the microtitre plate (Iwaki) was inoculated with 100 ml
yeast suspension. The cells were allowed to adhere to the well
bottoms by incubating at 37uC, 75 rpm for 1.5 h (adhesion phase).
Then, the biofilm was washed with 100 ml PBS to remove the non-
adherent cells, and 200 ml fresh medium was added to each well.
The biofilm was then incubated at 37uC, 75 rpm for 24 h. For the
screening assay, the small molecules (0.2 – 100 mg/ml) were added
to the biofilm before or after the adhesion phase. The effect of
SM21 on mature biofilms was further investigated by adding
SM21 (0.2 – 100 mg/ml) to the biofilm at 24 h and 48 h.
Cell viability of the treated biofilms was measured by the XTT
reduction assay [33]. The medium in each well was discarded, and
200 ml XTT solution was added. The XTT solution consisted of
40 ml XTT stock solution (1 mg/ml in PBS), 2 ml menadione
(0.4 mM in acetone) and 158 ml PBS. The microtitre plate was
incubated at 37uC in the dark for 3 h. Then, 160 ml XTT solution
from each well was transferred to a new microtitre plate, and the
absorbance was measured at 490 nm. The minimum inhibitory
concentration for biofilm (MICbiofilm) was determined as the
concentration that caused a 50% reduction in cell viability. All of
the assays were performed on three different occasions in
duplicate.
Anti-biofilm assay using an in vitro denture stomatitis
model
Cold-cured polymethylmethacrylate (PMMA) discs were pre-
pared according to the manufacturers’ instructions (Vertex RS,
Vertex-Dental BV, Zeist, The Netherlands) and as described
previously with some modifications [34]. In brief, transparent self-
polymerising acrylic powder was mixed with monomer liquid at a
1.5:1 ratio (w/v). This mixture was then immediately spread onto
and pressed tightly between two aluminium foil-covered glass
slides that had been secured with two binder clips to ensure similar
thickness and surface of the resultant acrylic strips. After curing for
15 min at 40uC, 2 – 6 bar, the strips were carefully retrieved and
cut into 1-cm2 squares. The strips were immersed in distilled water
for 7 days to remove excess monomers, and then disinfected in
70% alcohol for 1 min and washed thrice with sterile distilled
water. To simulate conditions present in the mouth and to
promote Candida adhesion, the strips were treated with saliva for
30 min at 37uC [35]. The saliva had been collected from five
healthy volunteers and centrifuged at 12,0006 g for 15 min at
4uC, and the resulting supernatant was stored at 270uC until use
[36].
C. albicans isolate BF-1, which was identified as a stronger
biofilm former in a previous study [36], was subcultured on SDA
one day before the assay. The yeast inoculum was standardised to
16107 CFUs/ml in YNB supplemented with 100 mM glucose.
The acrylic strips were placed in 24-well plates (Iwaki), and 1 ml
yeast inoculum was added to each well, completely covering the
acrylic strips. SM21 was added at MICbiofilm (1.56 mg/ml) before,
after, or both before and after the adhesion phase. The adhesion
phase was assessed 1.5 h after inoculation, and the plate was then
placed in a shaking incubator at 37uC. The cell viability of the
biofilm on the acrylic strips was quantified by the XTT reduction
assay and was also observed by confocal laser scanning microscopy
(Olympus Fluoview FV1000) after staining using a LIVE/DEAD
BacLight Viability Kit (Invitrogen).
Analysis of HWP1 expression
Engineered C. albicans strain PHWP1-GFP, which expressed GFP
under the control of either the HWP1 promoter, was gift from Dr.
B. P. Krom [37]. The PHWP1-GFP strain was used to test the effect
of SM21 on HWP1 expression. The strains were cultivated
overnight at 37uC in Lee’s medium containing SM21 at MIC
(0.2 mg/ml) or 26MIC (0.4 mg/ml). GFP expression was then
observed using confocal laser scanning microscopy (Olympus
Fluoview FV1000).
Fungal specificity assay
The disk diffusion assay (CLSI M44-A2) was also used to assess
the potential activity of SM21 against six bacterial species
(Escherichia coli, Lactobacillus acidophilus, Streptococcus mutans, Streptococ-
cus mitis, Streptococcus sanguinis and Aggregatibacter actinomycetemcomi-
tans). The bacteria were subcultured one day before the assay.
Bacterial cell suspensions were prepared for each sample at a
density of 16106 CFUs/ml and were then distributed evenly on
sheep blood agar plates with a spiral plater. Paper coupons
inoculated with 10 ml of drugs or controls (0.2 mg/ml SM21, 1 mg/
ml amphotericin B and 0.5 mg/ml caspofungin) were placed on the
agar. Chlorhexidine gluconate (0.2%) was used as a positive
(antibacterial) control, and PBS as a negative (harmless) control.
The plates were incubated anaerobically (except for the E. coli
plate) at 37uC for 24 h, and the diameters of inhibition zones were
measured.
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Figure 2. Dose-dependent Y-H inhibition of C. albicans SC5314 by the 20 primary hits under hyphal-inducing conditions. Cell
morphology of C. albicans SC5314 was observed by light microscopy after incubation in the presence of different concentrations of the 20 primary
hits under hyphal-inducing conditions (Lee’s medium and incubation at 37uC). The degree of Y-H inhibition was quantified by calculating the
percentage of hyphal cells in one hundred cells in a single sample. The average percentage of hyphae in the treated samples was normalised to the
average percentage of hyphae in the positive control (taken as 100%). Starting with the highest concentration, those small molecules showing no Y-H
inhibition were progressively eliminated in subsequent tests, which used lower concentrations. The assay identified eight potent Y-H inhibiting small
molecules. The standard deviations are shown for each sample, and asteriks indicate p-value ,0.05.
doi:10.1371/journal.pone.0085836.g002
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Effects on antifungal-resistant isolates
The efficacy of SM21 against 16 antifungal-resistant Candida
strains was evaluated by antifungal susceptibility tests (broth
microdilution and disk diffusion assays) as described above. The
strains were clinical blood isolates belonging to various Candida
spp., which had been obtained from Helsinki University Central
Hospital (Helsinki, Finland) and that had been confirmed to have
resistance to one or more antifungal agents by standard CLSI
antifungal susceptibility tests in our previous study [25].
Cytotoxicity assays
Primary human oral keratinocytes (HOKs) (ScienCell Research
Laboratories, Carlsbad, CA, USA) at passage three were seeded
into a 96-well plate (Iwaki) in oral keratinocyte medium (ScienCell
Research Laboratories). The serum-free medium contained 1%
oral keratinocyte growth supplement, 1% penicillin and 1%
streptomycin. Each well initially contained approximately 16104
HOKs, which were incubated in the presence of 5% CO2 at 37uC
(medium was changed every day) until the cells reached
confluence. A dilution series of SM21 (0.05 – 54.8 mg/ml) was
then supplied to the wells so that each well contained 200 ml of
medium in total. The plate was incubated at 37uC for 24 h, and
then the viability of the HOKs was determined by MTT assay (see
below).
T-75 flasks were also used to assess cell viability in the presence
of SM21. Besides HOKs, human gingival fibroblasts (HGFs) and
monocyte cell lines (ScienCell Research Laboratories) were also
used. Each cell line was seeded in T-75 flasks, and after confluence
was reached, 2 mg SM21 in 10 ml of growth medium (0.2 mg/ml
final concentration) was added to each flask. For comparison,
Figure 3. Anti-biofilm properties of SM10, SM12, SM16 and SM21. The small molecules were added to the C. albicans SC5314 biofilm (A)
before and after the adhesion phase; (B) after the adhesion phase; and incubated in 37uC for 24 h. The MICbiofilm was determined as the concentration
where the viability of the biofilm was reduced by 50% as compared with the positive control. SM21 had the lowest MICbiofilm among the four hits in
both cases, indicating its potent anti-biofilm property. NEG, negative control; POS, positive control.
doi:10.1371/journal.pone.0085836.g003
Figure 4. Structure of SM21. The molecular weight of SM21
(ChemBridge ID# 6633321) is 438 g/mol.
doi:10.1371/journal.pone.0085836.g004
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amphotericin B was used at the same concentration. After 24 h-
incubation at 37uC, MTT assay was performed to measure the cell
viability.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) is a yellow tetrazolium dye that is converted into a
purple compound by mitochondrial enzymes. MTT solution
(5 mg/ml) was prepared in growth medium and added to the wells
or flasks. After incubation at 37uC for 3 h in dark, the MTT
solution was discarded. The converted dye was solubilised with an
equal amount of DMSO. The absorbance of the converted dye
was measured at 570 nm with background subtraction at 650 nm.
The concentration at which the cell viability had dropped by 50%
was recorded as the cytotoxic concentration (CC50) [38].
Co-culture of C. albicans and HOKs
HOK culture was performed as mentioned above. HOKs at
passage three were seeded into an 8-well plate (ibidi, Martinsried,
Germany), which was compatible for the observation with
confocal laser scanning microscope. The cells were incubated at
37uC in the presence of 5% CO2 until confluence was reached,
with the medium changed every day. Each well contained
approximately 16105 HOKs at confluence. The cells were
washed once with PBS, and fresh medium without antibiotics (as
antibiotics could inhibit Candida growth) was added. A suspension
of C. albicans SC5314 (16104 CFUs/ml obtained by subculturing
on SDA plates and incubating at 37uC one day before inoculation)
was prepared in the growth medium (without antibiotics), and
100 ml of this cell suspension was added to each well. SM21 was
Figure 5. Y-H inhibition by SM21. C. albicans cell morphology was observed by light microscopy after incubation in the presence of SM21. (A)
SM21-mediated Y-H inhibition against strain CL1, a C. albicans clinical isolate. Under hyphal inducing conditions, hyphae could be observed in the
positive control (no SM21), whereas, no hyphae were observed in the SM21-treated samples. (B) Dose-dependent effect of SM21 on Y-H inhibition of
C. albicans SC5314 (16106 CFUs/ml). POS, positive control (no SM21). The degree of Y-H inhibition of each concentration was quantified by
calculating the mean percentage of hyphal cells in one hundred cells in quadruplicate. The average percentage of hyphae in the treated samples was
normalised to the average percentage of hyphae in the positive control (taken as 100%). MICY-H of SM21 was taken at 0.43 mg/ml, where only minimal
amount of hyphae was observed. mean differences between the tests and control were all statistically significant (p-value ,0.05).
doi:10.1371/journal.pone.0085836.g005
Table 1. Relationship between C. albicans cell density and
MICY-H of SM21.
Cell density MICY-H
(CFUs/ml) mg/ml mM
104 0.125 0.29
106 0.5 1.14
107 1 2.28
108 10 22.8
Results are the mean values of three independent experiments, performed in
duplicate for each of the ten clinical C. albicans isolates CL1 – CL10.
doi:10.1371/journal.pone.0085836.t001
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added at various final concentrations (0.5, 1 and 2 mg/ml),
whereas the positive controls contained only the growth medium.
The plate was then incubated at 37uC for 24 h in the presence of
5% CO2. The viability of HOKs and yeast cells was assessed by
confocal laser scanning microscopy using fluorescent probes
(LIVE/DEAD BacLight Viability Kit and LIVE/DEAD Viabil-
ity/Cytotoxicity Kit for mammalian cells; Invitrogen).
Ethics Statement
The animal studies strictly followed the recommendations in
‘‘Guide for the Care and Use of Laboratory Animals’’ published
by National Institutes of Health. The protocols were approved by
the Committee on the Use of Live Animals in Teaching and
Research (CULATR), University of Hong Kong (Permit Number:
2461-11).
Mouse model of systemic candidiasis
The mice used were 8-week-old male C57BL/6 mice that were
obtained from the Laboratory Animal Unit, University of Hong
Kong. Mouse model of systemic candidiasis was established
according to a previously described method [39], with modifica-
tions. The mice were injected via the tail vein with 100 ml cell
suspension of C. albicans SC5314 (16106 CFUs/ml) 3 h before the
start of antifungal treatment. Drugs were given to the mice twice a
day for 5 days via intraperitoneal injection. The test group (n = 5)
was treated with 0.01, 0.1, 1 and 10 mg/kg SM21 in 100 ml PBS,
while the control group (n = 5) was treated with PBS. The mice
were weighed every day. All of the mice were sacrificed after 5
days, and the kidneys were harvested (as most of the Candida cells
in systemic candidiasis murine models are found in the kidneys
[39]). The kidneys were divided into equal portions for fungal
burden determination and histopathological evaluation. For fungal
burden determination, the kidneys were weighed and then
homogenised in PBS, and the homogenates were serially diluted
before plating on SDA. The plates were incubated at 37uC, and
fungal burden was expressed as the ratio of colony forming units
(CFUs) to the organ weight. For histopathological analysis, organs
were fixed in 4% paraformaldehyde, embedded with paraffin wax
and stained with periodic acid-Schiff (PAS).
Mouse model of oral candidiasis
The murine model of oral candidiasis was established according
to a previously described method [40,41]. One day before
infection, C57BL/6 mice were immunosuppressed by subcutane-
ous injection of two doses of prednisolone (100 mg/kg body
weight), and the antibiotic tetracycline hydrochloride (0.83 mg/
ml) was administered in the drinking water. Immediately before
infection, the mice were anesthetised with 50 ml chlorpromazine
chloride (2 mg/ml) via intramuscular injection on each femur.
The oral cavities of the anesthetised mice were swabbed with a
sterilised cotton swab that had been dipped in a cell suspension of
C. albicans SC5314 (2.56107 CFUs/ml; from cultures grown
overnight at 37uC on SDA). Subsequently, 10 ml SM21 (200 mg/
ml; n = 3), 10 ml nystatin (10 mg/ml; n = 3) or 10 ml PBS (as a
control; n = 3) was administered to the mice by pipetting into their
mouths; this was done five times, at 3, 6, 12, 24 and 36 h after
inoculation. The mice were sacrificed 72 h after infection and
were immediately observed macroscopically for tongue lesions.
The tongue lesion degree was evaluated using a scoring system of 0
– 3 [40], with 0 denoting a healthy tongue surface and 3 the most
severe stage. The entire oral cavities of the mice were swabbed
with sterilised cotton swabs, which were then submerged in 500 ml
PBS and vortexed vigorously. The resultant suspension was spiral
plated on SDA, and the number of CFUs was counted after
incubation at 37uC for 24 h. In addition, the invasion of tongue
tissues by Candida was evaluated histologically by PAS staining, as
described above.
Propidium iodide uptake assay
Propidium iodide, a membrane-impermeable fluorescent dye
that binds to nucleic acids, is widely used to differentiate cells that
have damaged plasma membranes from healthy ones [42,43]. To
evaluate the effect of SM21 on the fungal plasma membrane, C.
albicans SC5314 cells (approximately 16103 CFUs/ml) were
obtained from logarithmic phase cultures and suspended in RPMI
1640 medium, as described above. The cells were then exposed to
sub-MIC of SM21 (0.1 mg/ml) for 1 h at 30uC with gentle
shaking. Subsequently, cells were harvested, incubated with
propidium iodide using a LIVE/DEAD BacLight Viability Kit
Figure 6. Inhibition of HWP1 expression by SM21. The inhibition
of HWP1 expression of SM21 was examined by C. albicans strain PHWP1-
GFP at MICY-H (0.43 mg/ml) and 26MICY-H (0.86 mg/ml). Fluorescence,
which indicated GFP expression under the control of the HWP1
promoter, was observed by confocal microscopy. In the control,
multiple hyphae layers were observed under hypha-inducing condi-
tions, however, only the fluorescence from the top layer could be
captured by the confocal microscopy. After treatment with SM21 at
MICY-H or 26MICY-H, no trace of fluorescence was detected.
doi:10.1371/journal.pone.0085836.g006
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Figure 7. Effect of SM21 on several bacterial species. Disk diffusion assays revealed that SM21 was harmless to E. coli, A.
actinomycetemcomitans, S. mutans, S. mitis, S. sanguinis, and L. acidophilus. P – PBS, C – chlorhexidine (0.2%), CA – caspofungin (5 mg), A –
amphotericin B (10 mg), SM – SM21 (2 mg).
doi:10.1371/journal.pone.0085836.g007
Novel Antifungal for Candida Infections
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(Invitrogen) for 15 min, and then observed by confocal microscopy
(Olympus FluoView FV1000).
Statistical analysis
One-way Analysis of Variance (ANOVA) was employed to
evaluate the mean difference between the control and the test
groups. Statistical significance of the data was analyzed using SPSS
software package (SPSS version 20; SPSS Inc, Chicago, IL, USA).
Data was considered significant if p-values are less than 0.05.
Results
Discovery of the lead compound
To obtain small molecule inhibitors of Candida spp., we first
screened 50,240 small molecules for inhibitors of the Y-H
transition in C. albicans, and 20 active compounds were identified.
Of these, eight compounds displayed strong dose-dependent Y-H
inhibition under hypha-inducing conditions for the reference
strain C. albicans SC5314 and ten clinical isolates of C. albicans
(Figure 2). Of these eight compounds, four (SM10, SM12, SM16
and SM21) formed inhibition zones in disk diffusion assays using
the standard reference strain C. albicans ATCC 90028, indicating
fungicidal activity (The result of SM21 is shown in Figure S1). In
addition, SM21 had the most potent anti-biofilm activity out of the
four compounds (Figure 3). Therefore, SM21 (molecular
weight = 438 g/mol, ChemBridge ID# 6633321), which had not
Table 2. MICs of SM21 and amphotericin B against a range of
Candida and other fungal species.
MIC (mg/ml)
Fungal strain SM21 AMB
C. albicans ATCC90028 0.2 0.2
C. albicans SC5314 0.2 0.2
C. albicans CL1 0.2 0.2
C. albicans CL2 0.2 0.4
C. albicans CL3 1.6 0.4
C. albicans CL3 1.6 0.4
C. albicans CL4 0.8 0.2
C. albicans CL5 1.6 0.2
C. albicans CL6 1.6 0.2
C. albicans CL7 0.8 0.2
C. albicans CL8 0.8 0.4
C. albicans CL9 1.6 0.4
C. albicans CL10 1.6 0.2
C. glabrata ATCC90030 1.6 0.4
C. krusei ATCC6258 0.4 0.4
C. tropicalis ATCC13803 0.8 0.8
C. parapsilosis ATCC22019 1.6 0.8
C. neoformans 0.4 0.4
A. fumigatus 6.25 1.56
P. marneffei 0.2 0.05
AMB – amphotericin B. The MICs of SM21 against the Candida isolates tested
ranged from 0.2 – 1.6 mg/ml, while the MICs of amphotericin B ranged from 0.2
– 0.8 mg/ml. The similar range of MICs suggested the comparable potency of
SM21 and amphotericin B. For the other fungal species, lower susceptibility of
SM21 against A. fumigatus was observed. Such trend was also observed for
amphotericin B.
doi:10.1371/journal.pone.0085836.t002
Figure 8. Effect of SM21 on C. albicans biofilm formation on
denture acrylic. (A) Confocal images of C. albicans biofilm after
treatment with SM21 and staining with fluorescent labels that
distinguish between live and dead cells. All cells were labeled with
the green fluorescence, while only the dead cells were labeled with red
fluorescence. (B) Biofilm cell viability, quantified by XTT reduction assay,
was reduced by 85% and 66%, respectively, when SM21 was added
before or after the adhesion phase. The reduced biofilm viability was
maximised (97%) when SM21 was added both before and after the
adhesion phase. The standard deviations of each sample are shown in
the graph, and all the mean differences between the control and test
(SM21) were statistically significant (p-value,0.05).
doi:10.1371/journal.pone.0085836.g008
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been previously identified as an antifungal agent, was chosen for
further study (Figure 4).
SM21 is a potent Y-H inhibitor
To further examine the Y-H inhibition of SM21, the phenotype
of a panel of Candida isolates, including reference strain C. albicans
SC5314 and ten C. albicans clinical isolates of oral origins was
observed under robust hypha-inducing condition in the presence
of SM21. In the control, where SM21 was not added, extensive
hyphae could be observed after 24-h incubation. In contrast, only
yeast cells, and not hyphae, could be observed in samples laced
with SM21 of concentration 0.43 mg/ml or higher (Figure 5A).
The MICY-H of SM21 was 0.43 mg/ml (equivalent to 0.98 mM)
(for 16106 CFUs/ml C. albicans SC5314; Figure 5B), which was
similar to the average MICY-H for ten clinical isolates (0.5 mg/ml)
(Table 1). Furthermore, the MICY-H was directly proportional to
the cell density (Table 1).
In addition, we used a C. albicans PHWP1-GFP strain to test
whether SM21 affected HWP1 expression. GFP was expressed in
candidal hyphae under untreated conditions (as observed by
confocal fluorescence microscopy; Figure 6). By contrast, no trace
of fluorescence could be detected from the SM21-treated cells at
both MICY-H and 26MICY-H, suggesting that SM21 influenced
HWP1 expression.
SM21 is active against fungi but not bacteria
An ideal antifungal agent should be active against fungal species
but not against bacteria. The antifungal activity of SM21 was
exhibited by disk diffusion assay and broth microdilution assay.
SM21 formed inhibition zones with C. albicans SC5314, C. albicans
ATCC 90028 and all of the 148 clinical isolates tested. The
average diameter of the inhibition zones of SM21 against these
isolates was 27.7 mm (range = 25 – 31 mm) (The growth
inhibition zones of SM21 against C. albicans SC5314 and C.
albicans ATCC 90028 were shown in Figure S1.). For the broth
microdilution assay, the MIC of SM21 against C. albicans ATCC
90028 was found to be 0.2 mg/ml, which was similar to that of the
conventional antifungal amphotericin B, suggesting a comparable
potency (Table 2). The MIC of SM21 for a wide range of Candida
spp. (including clinical isolates) and other fungal species (except A.
fumigatus) ranged from 0.2 to 1.6 mg/ml (Table 2). Lower
susceptibility to SM21 was noted with the fungus A. fumigatus
(MIC = 6.25 mg/ml), as was also observed for amphotericin B
(MIC = 1.56 mg/ml). SM21 did not inhibit the growth of any of
the six bacterial species evaluated in disk diffusion assay, implying
the fungal specificity of the novel molecule (Figure 7).
SM21 inhibits biofilm formation
We then assessed the activity of SM21 against Candida biofilm
formation. We first used a microtitre-plate biofilm model in which
SM21 was added to the 24-h and 48-h biofilm of C. albicans, C.
glabrata and C. krusei. SM21 demonstrated a lower MICbiofilm than
Table 3. MICbiofilm of SM21 against three different Candida
species.
MIC (mg/ml)
Candida species 24-h biofilm 48-h biofilm
SM21 AMB CASP SM21 AMB CASP
C. albicans 3.2 32 50 25 32 100
C. glabrata 3.2 16 50 25 16 100
C. krusei 3.2 32 50 25 32 100
Candida biofilms of 24-h or 48-h were incubated with serial dilution of SM21 for
24 h. Thereafter, the MICbiofilm of SM21 was determined as the concentration at
which the cell viability of the biofilm was reduced by 50% as compared with the
untreated control. (AMB – amphotericin B, CASP – caspofungin.)
doi:10.1371/journal.pone.0085836.t003
Figure 9. Effect of SM21 on a multidrug-resistant isolate. SM21
(SM) produced a clear inhibition zone in a disk diffusion assay against T-
1549, a C. guilliermondii strain with multidrug resistance to amphoter-
icin B (AMB), caspofungin (CASP) and fluconazole.
doi:10.1371/journal.pone.0085836.g009
Table 4. MICs of SM21 for antifungal-resistant Candida
strains.
Drug-resistant isolates
Antifungal-
resistance MIC (mg/ml)
C. albicans T1675 F,I 0.5
C. parapsilosis T1677 C,F,I,K,V 1
C. parapsilosis T1565 C,I 1
C. parapsilosis T1545 C 1
C. parapsilosis T1688 I 0.5
C. glabrata T1585 F,I,K,V 1
C. glabrata T1672 I,K 0.5
C. glabrata T1570 I 0.5
C. tropicalis T1427 I 1
C. tropicalis T789 I 1
C. tropicalis T1148 I 0.5
C. krusei T1472 F,I,K 1
C. krusei T1266 F 0.5
C. krusei T1562 F 1
C. krusei T1266 F 1
C. guilliermondii T1549 A,C,F 1
A – amphotericin B, C – caspofungin, F – fluconazole, I – itraconazole, K –
ketoconazole, V – voriconazole.
doi:10.1371/journal.pone.0085836.t004
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amphotericin B and caspofungin for both 24-h and 48-h biofilm
(Table 3). In an in vitro model of denture stomatitis, SM21
effectively prevented candidal adhesion and biofilm development
on denture acrylic surfaces (Figure 8A). In this model, biofilm
viability was reduced by 85%, 66% and 97%, when SM21 was
added before, after, or both before and after the 1.5 h adhesion
phase respectively (Figure 8B). Summarized from the two assays,
SM21 was effective against mature Candida biofilm and inhibited
biofilm formation on denture acrylic surfaces.
SM21 is active against antifungal-resistant Candida spp.
The emergence of antifungal-resistant Candida strains has led to
the urgent need of new antifungal agents. All of the drug-resistant
isolates tested were susceptible to SM21. For instance, a clear
SM21 inhibition zone was observed for T-1549, a multidrug-
resistant C. guilliermondii strain (Figure 9). The MIC of SM21
against drug-resistant Candida isolates in broth microdilution assays
ranged from 0.5 to 1 mg/ml (Table 4), which was marginally
higher than the MIC for C. albicans ATCC 90028.
SM21 displays low toxicity to human cells
Cytotoxicity assays performed in a 96-well plate revealed the
CC50 of SM21 to be 3.4 mg/ml (7.8 mM) for HOKs. In assays
conducted in T-75 flasks, 0.2 mg/ml SM21 reduced the viability of
HOKs by 12% compared with the untreated controls, which is
lower than the 22% reduction observed for amphotericin B.
Treatment with SM21 or amphotericin B caused, respectively, a
20% or 5% reduction in monocyte viability compared with the
controls. Neither SM21 nor amphotericin B affected the viability
of HGFs (Figure 10).
SM21 prevents candidal invasion of human cells in vitro
To test whether SM21 was able to prevent C. albicans invasion of
human cells, a co-culture of HOKs and C. albicans SC5314 was
exposed to various concentrations of SM21. In the co-culture
control (in which no SM21 was present), many hyphae were
observed. The hyphal invaded and caused the death of most of the
HOKs (Figure 11). At 0.5 mg/ml SM21, Candida hyphae could still
be observed, however, the proportion of live HOKs increased. At
2 mg/ml and 4 mg/ml SM21, most of the HOKs were alive, and
no Candida were observed. Therefore, this SM21 concentration
was safe to HOKs and was sufficient to prevent Candida from
invading the human cells.
SM21 improves survival in a mouse model of systemic
candidiasis
A mouse model of systemic candidiasis was used to assess the in
vivo activity of SM21. Infection was established in mice by injecting
100 ml of 16106 CFUs/ml C. albicans SC5314 via tail vein. The
test group was treated with 0.01, 0.1, 1 and 10 mg/kg SM21,
while control group was treated with PBS. At day 5 (the
experimental end point) after infection with C. albicans, all of the
untreated mice with systemic candidiasis had died, whereas all of
the SM21-treated mice were alive (Figure 12A). The fungal
burden in the kidneys was significantly lower in the SM21-treated
mice than in the untreated ones (Figure 12B). Moreover, white
Candida lesions were visible covering the surfaces of the kidneys of
the untreated mice, while the kidneys of the SM21-treated mice
appeared healthy (Figure 12C). Clusters of Candida hyphae were
easily identified in PAS-stained kidneys of the untreated mice,
whereas very few Candida cells were observed in the kidney
parenchyma of the SM21-treated mice (Figure 12D). These results
indicated that SM21 was effective in preventing systemic spread
and invasion of Candida in the mouse model.
SM21 reduces tongue lesions in a mouse model of oral
candidiasis
We then assessed the effects of SM21 and nystatin treatments in
a mouse model of oral candidiasis established by inoculating C.
albicans SC5314 (2.56107 CFUs/ml) in the oral cavities of the
mice. Treatment was given to the mice at five time intervals.
Immediately after sacrifice (72 h after inoculation), scores were
assigned for tongue lesions from 0 (healthy tongue surface) to 3
(most severe stage). Thick oral thrush was observed in the
untreated mice (score = 3; Figure 13A). Tongue lesions in the
nystatin-treated mice were less severe than in the untreated
controls, although considerable oral thrush was noted at the back
of the tongue (score = 2). Compared with the other two groups,
Figure 10. Cytotoxicity of SM21 against three primary cell lines. HOK – human oral keratinocyte, HGF – human gingival fibroblast, AMB –
amphotericin B. Both SM21 (0.2 mg/ml) and amphotericin B (0.2 mg/ml) reduced the viability of HOKs and monocytes. SM21 caused a reduction of
12% in cell viability compared with the untreated controls, which is lower than the 22% reduction observed for amphotericin B. Treatment with SM21
or amphotericin B caused, respectively, a 20% or 5% reduction in monocyte viability compared with the controls. Neither SM21 nor amphotericin B
affected the viability of HGFs.
doi:10.1371/journal.pone.0085836.g010
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SM21-treated mice displayed the least severe tongue lesions
(score = 1). Moreover, Candida cell counts from tongue swabs of the
SM21-treated mice (4.56102 CFUs/ml) were consistently lower
than those of the control mice (4.86103 CFUs/ml) and the
nystatin-treated animals (6.06102 CFUs/ml). Numerous candidal
hyphae were noted in PAS-stained tongue sections of the
untreated mice, whereas less profuse candidal growth was
observed in samples from the mice treated with SM21 or nystatin
(Figure 13B).
SM21 affects permeability of the fungal cell membrane
To shed some light on the mechanism of action of SM21, we
performed propidium-iodide uptake assays. Candida exposed to
sub-MIC of SM21 (0.1 mg/ml) displayed abundant propidium
iodide uptake, indicating cell membrane damage (Figure 14).
Therefore, the molecular target of SM21 might be a component of
the cell membrane.
Discussion
A handful of small molecules have been reported to possess
activity against C. albicans [29,44–47]. However, the therapeutic
potential of these small molecules is unclear, because they have
been evaluated mainly for the ability to inhibit C. albicans virulence
properties such as Y-H transition or biofilm formation in vitro. It
has been hypothesised that arresting Candida in the unicellular
yeast form would result in reduced virulence. This hypothesis is
supported by the finding that non-filamentous C. albicans mutants
are not virulent in a mouse infection model [48], however, this is
only relevant to C. albicans. Some NAC species (which do not form
true hyphae) are also virulent. Moreover, the strategy of inhibiting
virulence factors could facilitate the emergence of resistant strains
because it only inhibits the growth of virulent strains but does not
kill them. Complete elimination of pathogen is clearly a safer
option; therefore, fungicidal drugs are preferred.
Figure 11. Effect of SM21 treatment in Candida–HOK co-culture model. The viability of co-cultured HOKs and yeast cells in the presence of
SM21 was assessed by confocal laser scanning microscopy using fluorescent probes. In the untreated control, many hyphae were observed, and most
of the HOKs were dead (the nuclei of the dead cells were labeled with red fluorescence). Samples containing 0.5 mg/ml SM21 still included many
hyphae, but they contained more live HOKs than the untreated control. Samples containing 1 mg/ml or 2 mg/ml SM21 included few yeast cells and no
hyphae, and most of the HOKs were alive. Magnification= 206 (unless specified otherwise).
doi:10.1371/journal.pone.0085836.g011
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For all of the above reasons, we set out to identify new
antifungal compounds with both fungicidal and anti-virulence
properties. To this end, we first screened for Y-H inhibitors a
library of 50,240 small molecules. It should be noted that the Y-H
inhibitor screening assay selects for molecules that block the
change from the yeast form of C. albicans to the hyphal form, as
assessed by morphology. Therefore, this assay does not discrim-
inate between molecules that inhibit the growth of C. albicans,
which would also prevent the Y-H transition, and true inhibitors of
the Y-H transition. Moreover, conventional antifungal agents such
as fluconazole, amphotericin B and 5-fluorocytosine, whose
mechanisms are not directly related to Y-H inhibition, also inhibit
the formation of hyphae [49]. Nevertheless, this ambiguity of the
screening assay was favourable for increasing the hit rate in our
initial screening.
After several in vitro analyses of the antifungal properties of 20
small molecules identified by our initial screening, we found that
one of them, SM21, is a potent Y-H inhibitor that is effective at
Figure 12. Effect of SM21 treatment on a mouse model of systemic candidiasis. (A) Survival rate of the mice. After the experimental period
(day 5), the survival rates for untreated and SM21-treated mice were 0% and 100%, respectively. (B) Fungal burden in the kidneys of the mice (Error
bars indicate standard deviation). SM21 significantly reduced the renal fungal burden in the mice by an order of magnitude of 3 (p-value of mean
difference ,0.05). (C) Surfaces of the kidneys of untreated mice were covered with Candida lesions, while the kidneys of the SM21-treated mice
appeared healthy. (D) PAS staining of the kidneys. Candida hyphae (indicated by black arrows) were easily spotted in the kidneys of untreated mice,
whereas few were detected in the kidneys of SM21-treated mice.
doi:10.1371/journal.pone.0085836.g012
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low concentrations. Among the Y-H inhibitors identified in the
study by Midkiff et al, the lowest MICY-H is 20 mM for 1610
4 cells
[46], which is much higher than the SM21 MICY-H (0.98 mM for
16106 CFUs/ml). The number of Candida decreased after SM21
treatment in vitro, suggesting that this compound is fungicidal.
Fungicidal drugs inhibit Y-H transition at sub-MIC, whereas
fungistatic drugs inhibit Y-H transition only at much higher
concentrations than their MIC [50]. It has been suggested that
fungicidal drugs inhibit hyphal development and the budding
process, whereas fungistatic drugs inhibit only the budding process
[50].
The in vitro antifungal activity of SM21 is comparable to that of
commonly used antifungal drugs such as amphotericin B (a
polyene). In disk diffusion assays, SM21 forms clear inhibition
zones that resemble those produced by polyenes and echinocan-
dins, and unlike the partial inhibition zones formed by azoles, for
which trailing endpoint is observed [51]. The MIC of SM21 in
broth microdilution assays for a wide range of C. albicans strains
(0.2 – 1.6 mg/ml) is similar to the MIC of amphotericin B, which
has been considered to be a gold standard of antifungal agents
[52]. Moreover, the activity of SM21 against C. albicans biofilms
grown on microtitre plates is similar or more potent than that of
Figure 13. Effect of SM21 treatment on a mouse model of oral candidiasis. (A) The degree of tongue lesions in the oral candidiasis mouse
model was evaluated by a scoring system of 0 – 3 (0 denotes healthy tongue surface and 3 denotes the most severe stage). A thick oral thrush
(score = 3) was observed in untreated mice. Nystatin-treated mice displayed less oral thrush on the tongue surface than the untreated controls, but a
considerable amount of oral thrush was observed at the back of the tongue (score = 2). SM21-treated mice displayed the least severe tongue lesions
(score = 1). (B) PAS staining of tongue sections. Abundant hyphae (indicated by black arrows) covered most of the tongue surface in the untreated
mice, whereas comparatively fewer hyphae were observed in nystatin- and SM21-treated mice.
doi:10.1371/journal.pone.0085836.g013
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amphotericin B or caspofungin (Table 3). The MICbiofilm of SM21
increases as the biofilm matures, a common phenomenon among
antifungal agents [53].
Attachment to mucosal tissue and biofilm formation are the
basis of mucosal candidiases such as oral candidiasis and Candida-
associated denture stomatitis [4,9]. SM21 is effective at reducing
candidal attachment to denture acrylic surfaces and inhibiting
biofilm development in an in vitro model of denture stomatitis.
These promising data indicate that SM21 might have potential as
a denture disinfectant or as the active ingredient in an oral drug
delivery system.
We also analysed the in vivo effects of SM21 treatment on mouse
models of oral and systemic candidiasis. We showed that oral
rinses containing 200 mg/ml SM21 significantly reduced tongue
lesions in the oral candidiasis mouse model. Moreover, the efficacy
of SM21 was better than that of nystatin, which is the most
commonly used antifungal for oral candidiasis [4]. In particular,
oral thrush was observed at the back of the tongues in nystatin-
treated mice (indicating oropharyngeal candidiasis) but not in
SM21-treated animals. However, very little is known about the
pharmacokinetics and pharmacodynamics of nystatin in murine
models of oral candidiasis, and therefore the concentration used in
our experiments (10 mg/ml) might not be high enough to produce
an optimal outcome. In addition, the duration of an oral rinse
cannot be controlled in a mouse model.
We evaluated SM21 toxicity against human cell lines in vitro. In
contrast to bacteria, the cells of fungi and humans are eukaryotic
and, therefore, very similar. This similarity is a major hurdle in
antifungal development, which requires drug targets to be fungus-
specific to avoid undesirable toxicity [54]. We found that the CC50
of SM21 for HOKs is 7.8 mM (3.4 mg/ml) in a 96-well plate assay.
Although this value is lower than the minimum CC50 (16 mM)
reported for 14 antifungal compounds that were identified by
LaFleur et al (tested against human fibroblasts in 96-well plates;
[45]), the CC50 of SM21 is still higher than its MIC (0.2 mg/ml),
which indicates that there is a range of concentrations at which
SM21 could be used as an antifungal agent without causing
significant toxicity to human cells. Indeed, no detrimental effects
were observed in mice that had been injected with SM21 doses as
high as 10 mg/kg twice daily. In addition, SM21 does not seem to
have antibacterial properties, indicating that its target is present in
fungi but not in bacteria.
We demonstrated that intraperitoneal administration of SM21
is an effective treatment for systemic candidiasis in a mouse model.
An SM21 dose of 0.1 mg/kg or higher twice daily beginning 3 h
post-infection significantly reduced fungal burden in non-neutro-
penic mice. The in vivo efficacy of SM21 is similar to that of
conventional antifungal agents in comparable non-neutropenic
mouse models of systemic C. albicans candidiasis. For example, the
intraperitoneal ED50 (50% effective dose) of fluconazole is
4.56 mg/kg when administered to the mice as a single dose 5 h
after infection; the animals were sacrificed 24 h later [55].
Intraperitoneal amphotericin B (1 mg/kg dose daily) decreases
fungal burden in mouse kidneys from day 1 to day 3 after infection
(with treatment beginning 24 h after infection) [56]. In addition,
intravenous micafungin treatment (0.125 mg/kg or higher daily
dose, starting 1 h after infection for 4 days) prolongs survival of
infected mice [57]. However, it is difficult to compare the effective
doses from different studies because there is no standard protocol,
and differences in the Candida strain, inoculum size, mouse strain,
mouse immune status and the start and interval of antifungal
therapy could interfere with the outcome. In addition, there are
differences in the in vivo drug efficacy among normal and
neutropenic murine models, which may be due to the possible
interactions between the drug and host defence mechanisms [56].
Detailed pharmacodynamics-pharmacokinetics studies would need
to be performed in the future to determine the time/concentration
relationship of the drug at the infection sites and, thus, to generate
the dosing regimens that produce the best treatment outcome in
vivo [58].
SM21 is effective against antifungal-resistant clinical isolates,
indicating that its mechanism of action is distinct from those of
conventional antifungals. Our preliminary results described here
indicated that SM21 could be targeting a component of the fungal
cell membrane. Nevertheless, extensive assays are needed to
elucidate the mechanism of action of this new drug.
In conclusion, in the present study we have characterised novel
antifungal small molecule, SM21 using a comprehensive set of in
vitro and in vivo assays. Our findings support SM21 as a promising
compound for development of novel antifungal agent for treating
local and systemic candidiasis, which could bring enormous
benefit to the patients suffering from this recalcitrant fungal
pathogen.
Figure 14. Confocal microscopic analysis of propidium-iodide uptake assays. (A) Untreated control samples showed hyphal elements of
live C. albicans cells. (B) C. albicans treated with sub-MIC of SM21 (0.1 mg/ml) showed propidium iodide uptake (labeled by red fluorescence),
indicating cell membrane damage. Some of the cells (denoted by white arrow) were non-viable.
doi:10.1371/journal.pone.0085836.g014
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Supporting Information
Figure S1 Antifungal susceptibility test (disk diffusion
assay) of SM21 against C. albicans SC5314 and C.
albicans ATCC 90028. 21 – SM21, A – amphotericin B, F –
fluconazole, K – ketoconazole. Growth inhibition zones were
observed for SM21 against the two C. albicans strains tested. The
growth inhibition zones produced by SM21 were clear, similar to
those produced by amphotericin B, but dissimilar to those
produced by fluconazole. This phenomenon suggested that
SM21 is, like amphotericin B, fungicidal in nature.
(TIF)
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